Shanghai Junshi Biosciences Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SHJBF research report →
Price Chart
About the company
Shanghai Junshi Biosciences Co. , Ltd. is a biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of various medicinal products.
- CEO
- Cong Li
- IPO
- 2021
- Employees
- 2,903
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on SHJBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.84B
- P/E
- -58.34
- Fwd P/E
- 21.06
- PEG
- -0.80
- P/S
- 14.18
- P/B
- 6.60
- EV/EBITDA
- -71.27
- Div Yield
- 0.00%
- Gross Margin
- 78.56%
- Op Margin
- -30.43%
- Net Margin
- -24.26%
- ROE
- -10.78%
- ROIC
- -6.50%
Latest fiscal year · YoY change
- Revenue
- $2.43B+24.9%
- Gross Profit
- $1.76B+21.5%
- Op Income
- $-909,470,904
- Net Income
- $-851,825,036+33.6%
- EPS
- $-0.84+35.4%
- OCF Growth
- +67.7%
- FCF Growth
- +43.1%
- 52W High
- $4.23
- 52W Low
- $1.97
- 50D MA
- $3.35
- 200D MA
- $3.28
- Beta
- 0.58
- RSI (14)
- 100
- Avg Volume
- 119
No earnings-call transcripts are available for SHJBF yet.
- Free Float
- 25.2%
- Shares Outstanding
- 1.45B
- Float Shares
- 363.95M
Our SHJBF coverage
Recent articles, reports, and earnings notes.
No research on SHJBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SHJBF report →Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
globenewswire.com · Jul 21
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
globenewswire.com · May 26
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
globenewswire.com · Apr 20
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
globenewswire.com · Mar 13
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
globenewswire.com · Mar 9
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
globenewswire.com · Feb 24
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
prnewswire.com · Feb 24
Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
globenewswire.com · Nov 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.